NuCana is trading at $1.09, down 6.84%, with no clear company-specific catalyst identified for the October 2 decline.
- The latest reported company news was a September 30 patent announcement.
- The broader market is higher, so market-wide weakness does not explain the decline. Reported coverage said NuCana’s October 1 close was already down 13.33%.
- Current volume information is unavailable.